Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 892

Yesterday, the Whitehouse announced that the USA and the EU (European Union) signed an administrative agreement to bring AI experts together to advance AI research as prior outlined in the U.S.-EU Trade and Technology Council (TTC) commitment.

This effort will further drive responsible advancements in AI to advance global complex challenges and develop a joint integrated research approach to achieve benefits in key research domains: extreme weather and climate forecasting, emergency response management, health and medicine, electric grid optimization, and agriculture optimization.

This article focuses on the AI leadership with the USA and the European Union in signing a new administrative agreement to do joint AI research in key global challenge areas like: climate change, healthcare, agriculture, etc.

Read more | >

Year 2022 😗

Experts believe it is destined to become the world’s fifth major cancer treatment after surgery, chemotherapy, radiotherapy and immunotherapy.

The light-activated therapy forces cancer cells to glow in the dark, helping surgeons remove more of the tumours compared with existing techniques – and then kills off remaining cells within minutes once the surgery is complete. In a world-first trial in mice with glioblastoma, one of the most common and aggressive types of brain cancer, scans revealed the novel treatment lit up even the tiniest cancer cells to help surgeons remove them – and then wiped out those left over.

Trials of the new form of photoimmunotherapy, led by the Institute of Cancer Research, London, also showed the treatment triggered an immune response that could prime the immune system to target cancer cells in future, suggesting it could prevent glioblastoma coming back after surgery. Researchers are now also studying the new treatment for the childhood cancer neuroblastoma.

Continue reading “Scientists harness light therapy to target and kill cancer cells in world first” | >

A research group at the University of Tokyo, led by Assistant Professor Kunihiko Morihiro and Professor Akimitsu Okamoto from the Graduate School of Engineering, were inspired to create a new anticancer drug using artificial DNA. “We thought that if we can create new drugs that work by a different mechanism of action from that of conventional drugs, they may be effective against cancers that have been untreatable up to now,” said Okamoto.

Nucleic acid.

Any substance that when dissolved in water, gives a pH less than 7.0, or donates a hydrogen ion.

Read more | >

Scientists at University of California San Diego School of Medicine have developed an artificial intelligence (AI)-based strategy for discovering high-affinity antibody drugs.

In the study, published January 28, 2023 in Nature Communications, researchers used the approach to identify a new antibody that binds a major cancer target 17-fold tighter than an existing antibody drug. The authors say the pipeline could accelerate the discovery of novel drugs against cancer and other diseases such as COVID-19 and rheumatoid arthritis.

In order to be a successful , an antibody has to bind tightly to its target. To find such antibodies, researchers typically start with a known antibody and use bacterial or to produce a series of new antibodies with variations of that sequence. These mutants are then evaluated for their ability to bind the target antigen. The subset of antibodies that work best are then subjected to another round of mutations and evaluations, and this cycle repeats until a set of tightly-binding finalists emerges.

Read more | >

But every once in a while, an idea is so powerful and so profound its effects are felt much faster.

That’s been the case with CRISPR gene editing, which celebrates a 10th anniversary this month. It has already had a substantial impact on laboratory science, improving precision and speeding research, and it has led to clinical trials for a handful of rare diseases and cancers.

Over the next decade, scientists predict, CRISPR will yield multiple approved medical treatments and be used to modify crops, making them more productive and resistant to disease and climate change.

Read more | >

New video: Stephanie Dainow, Executive Director at Lifespan.io / Lifespan Extension Advocacy Foundation, at #RejuvenationStartupSummit 2022.

Stephanie speaks about Lifespan.io advocating for the development of medical technologies to rejuvenate aged tissues and organs.

Enjoy →

For more summit videos and regular updates, visit: youtube.com/user/foreverhealthyorg

Continue reading “Stephanie Dainow at Rejuvenation Startup Summit 2022” | >

Connectome harmonic decomposition (CHD) generalises the mathematics of the Fourier transform to the network structure of the human brain. The traditional Fourier transform operates in the temporal domain (Fig. 1a): decomposition into temporal harmonics quantifies to what extent the signal varies slowly (low-frequency temporal harmonics) or quickly (high-frequency temporal harmonics) over time (Fig. 1b). Analogously, CHD re-represents a spatial signal in terms of harmonic modes of the human connectome, so that the spatial frequency (granularity) of each connectome harmonic quantifies to what extent the organization of functional brain signals deviates from the organization of the underlying structural network (Fig. 1c, d). Therefore, CHD is fundamentally different from, and complementary to, traditional approaches to functional MRI data analysis. This is because CHD does not view functional brain activity as composed of signals from discrete spatial locations, but rather as composed of contributions from distinct spatial frequencies: each connectome harmonic is a whole-brain pattern with a characteristic spatial scale (granularity)—from an entire hemisphere to just a few millimetres.

On one hand, this means that CHD is unsuitable to address questions pertaining to spatial localisation and the involvement of specific neuroanatomical regions; such questions have been extensively investigated within the traditional framework of viewing brain activity in terms of spatially discrete regions, and several previous studies have implicated specific neuroanatomical regions in supporting consciousness33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49. On the other hand, CHD enables us to consider how brain activity across states of consciousness is shaped by the brain’s distributed network of structural connections, reflecting the contribution of global patterns at different spatial scales—each arising from the network topology of the human connectome. We emphasise that neither approach is inherently superior, but rather they each provide a unique perspective on brain function: one localised, the other distributed.

Read more | >

BREAKING:

@Pfizer.

Exploring “Mutating” COVID-19 Virus For New Vaccines.

“Don’t tell anyone this
There is a risk
have to be very controlled to make sure this virus you mutate doesn’t create something
the way that the virus started in Wuhan, to be honest.”

#DirectedEvolution

Continue reading “Do you think this is something to be concerned about?” | >

CRISPR gene editing created the G795A amino acid which was introduced to microglia derived from human stem cells. Researchers were able to transplant the donor microglia immune cells into humanized rodent models while administering an FDA-approved cancer drug called pexidartinib. The inclusion of the amino acid cause the donated microglia to thrive and resist the drug, while the host microglia died. The findings open the door for new methods of using microglia to treat a range of neurodegenerative disorders.

Read more | >